These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11723043)

  • 21. Ranolazine: a novel agent that improves dysfunctional sodium channels.
    Pham DQ; Mehta M
    Int J Clin Pract; 2007 May; 61(5):864-72. PubMed ID: 17493093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.
    Morrow DA; Scirica BM; Karwatowska-Prokopczuk E; Murphy SA; Budaj A; Varshavsky S; Wolff AA; Skene A; McCabe CH; Braunwald E;
    JAMA; 2007 Apr; 297(16):1775-83. PubMed ID: 17456819
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is randomization to placebo safe? Risk in placebo-controlled angina trials: angina risk meta-analysis.
    Glasser SP; Willard J; Defelice A; Lawrence J; Hung J; Obot E; Girton J; Targum S; Throckmorton D; Mangano D; Lipicky RJ
    Cardiology; 2011; 120(3):174-81. PubMed ID: 22261892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Azimilide: Search for an effective and well-tolerated anti-arrhythmia agent].
    Z Kardiol; 1999 Oct; 88(10 Suppl):1-2. PubMed ID: 10586493
    [No Abstract]   [Full Text] [Related]  

  • 25. Conventional and novel drug therapeutics to relief myocardial ischemia.
    Dvir D; Battler A
    Cardiovasc Drugs Ther; 2010 Aug; 24(4):319-23. PubMed ID: 20658184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardioprotection by opening of the K(ATP) channel in unstable angina. Is this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil. CESAR 2 investigation. Clinical European studies in angina and revascularization.
    Patel DJ; Purcell HJ; Fox KM
    Eur Heart J; 1999 Jan; 20(1):51-7. PubMed ID: 10075141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [What is the role of pravastatin in the secondary prevention of coronary disease?].
    Mahé I
    Presse Med; 1999 Apr; 28(13):691. PubMed ID: 10228480
    [No Abstract]   [Full Text] [Related]  

  • 28. [Progress in the clinical use of anti-arrhythmic drugs (I)].
    Li WZ
    Zhonghua Er Ke Za Zhi; 2003 Oct; 41(10):735-7. PubMed ID: 14731351
    [No Abstract]   [Full Text] [Related]  

  • 29. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial.
    Morrow DA; Scirica BM; Karwatowska-Prokopczuk E; Skene A; McCabe CH; Braunwald E;
    Am Heart J; 2006 Jun; 151(6):1186.e1-9. PubMed ID: 16781216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial.
    Wilson SR; Scirica BM; Braunwald E; Murphy SA; Karwatowska-Prokopczuk E; Buros JL; Chaitman BR; Morrow DA
    J Am Coll Cardiol; 2009 Apr; 53(17):1510-6. PubMed ID: 19389561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognosis of patients with unstable angina or acute myocardial infarction treated with calcium channel antagonists.
    Ferrari R
    Am J Cardiol; 1996 Jun; 77(16):22D-25D. PubMed ID: 8677893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical experience with ranolazine in a veteran population with chronic stable angina.
    Reeder DN; Gillette MA; Franck AJ; Frohnapple DJ
    Ann Pharmacother; 2012 Jan; 46(1):42-50. PubMed ID: 22215689
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ranolazine: focusing on angina pectoris.
    McCullough PA
    Drugs Today (Barc); 2006 Mar; 42(3):177-83. PubMed ID: 16628259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The azimilide post-infarct survival evaluation (ALIVE) trial.
    Camm AJ; Karam R; Pratt CM
    Am J Cardiol; 1998 Mar; 81(6A):35D-39D. PubMed ID: 9537221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of calcium channel blocking agents in the management of ischaemic heart disease.
    Braunwald E; Muller JE; Stone PH
    Eur Heart J; 1985 Jan; 6 Suppl A():31-6. PubMed ID: 3996436
    [No Abstract]   [Full Text] [Related]  

  • 36. [Calcium, calcium antagonists and coronary insufficiency].
    Lablanche JM; Bertrand ME
    Rev Prat; 1988 Nov; 38(27):1971-4. PubMed ID: 3206147
    [No Abstract]   [Full Text] [Related]  

  • 37. Which calcium channel blocker for ischaemic heart disease?
    Tan K; Lewis S
    Br J Clin Pract; 1992; 46(1):58-62. PubMed ID: 1419556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New antiarrhythmic agents for atrial fibrillation.
    Conway DS; Lip GY
    Curr Opin Investig Drugs; 2001 Jan; 2(1):87-92. PubMed ID: 11527018
    [No Abstract]   [Full Text] [Related]  

  • 39. Newer antiarrhythmic drugs.
    Gupta AK; Maheshwari A; Thakur RK; Lokhandwala YY
    Indian Heart J; 2001; 53(3):354-60. PubMed ID: 11516042
    [No Abstract]   [Full Text] [Related]  

  • 40. Dalteparin for unstable angina and non-Q-wave myocardial infarction.
    Borja J
    Arch Intern Med; 2000 Nov; 160(20):3169-70. PubMed ID: 11074753
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.